Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Institut Gustave Roussy, Villejuif, France

Survival: 9.1 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: France
City/State/Province: Villejuif
Hospital: Institut Gustave Roussy
Journal: Link
Date: 2/2014

This phase 2 study involved previously treated advanced non-small cell lung cancer patients who were divided into two treatment groups. In group A, there were 66 patients with a median age of 60 years; 54.5% were men. Group B had 67 patients with a median age of 60.5 years and 49.3% were men.

Patients in group A were treated with the biological therapy agents everolimus (an inhibitor of mTOR) and erlotinib (a tyrosine kinase inhibitor of the EGFR protein).

Patients in group B were treated with erlotinib alone.

There was one treatment-related death in group A due to heart attack. Grade 4 anemia and grade 3 stomatitis were also reported.

There was one treatment-related death in group B due to anaphylactic shock. Grade 4 shortness of breath was also reported.

The median overall survival rates for groups A and B were 9.1 and 9.7 months, respectively.

This study was supported by Novartis.

Correspondence: Dr. Benjamin Besse; email:

E-mail to a Friend Email Physician More Information